Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union


Agilent Technologies Inc. (NYSE: A) today announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR regulation.

This launch of IVDR-compliant Class A products ensures that labs in the EU who rely on Agilent IVDR instruments, kits, and reagents in their diagnostic workflows will continue to be able to use these products without disruption.

The In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746 is a new, harmonized regulatory framework established to ensure the present and future safety and performance of in vitro diagnostic (IVD) medical devices in the European Union market. The IVDR regulation replaces the previous IVDD directive, under which many Agilent products have been CE-IVD marked, indicating IVDD compliance. The launch represents a significant milestone for the Agilent organization, which faced substantial hurdles due to the COVID pandemic and related supply-chain challenges.

“Agilent shares the European Commission's vision of enhanced patient safety and transparency,” said Jenipher Dalton, senior vice president of Global Quality and Regulatory Affairs at Agilent. “We remain committed to providing high-quality solutions for delivering the testing results that physicians and patients in the EU rely on. Our multi-disciplinary team really came together to make this a seamless transition, and this result is a testament to their dedication and professionalism.”

Agilent Class A IVDR-compliant products span the entire Agilent product portfolio, from qPCR and NGS preparation instruments to H&E stains, staining instruments, and conjugated secondary antibody reagents.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005431/en/

Agilent Technologies Inc. Aktie

130,68 €
0,98 %
Leicht aufwärts geht es heute für die Agilent Technologies Inc. Aktie. Seit gestern notiert das Papier um 0,98 % höher.
Aktuell gibt es mit 16 Buy-Einschätzungen und 4 Sell-Einschätzungen ein positives Sentiment für die Agilent Technologies Inc. Aktie.
Das Kursziel von 133 € für Agilent Technologies Inc. weist auf ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 130.68 € hin.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare